Investigating the Role of Reticulon 3 in Modulating Dengue Virus Exosome Loading
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 486935
Grant search
Key facts
Disease
Denguestart year
2023Known Financial Commitments (USD)
$4,405.32Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Gwanyama BellaResearch Location
CanadaLead Research Institution
INRS - (Québec, QC)Research Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Disease pathogenesis
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Dengue fever is a mosquito-borne viral illness caused by the Dengue virus (DENV) that affects millions of people around the world and is a potential pandemic threat. Exosomes, which are vesicles secreted by infected cells, play an important role in DENV infection and disease pathogenesis. Reticulon 3 (RTN3) is a recently discovered membrane protein that is thought to play a role in regulating Flavivirus exosome loading, especially during hepatitis C virus (HCV) infection. The goal of this project is to study the role of RTN3 in modulating DENV exosome loading during disease pathogenesis. To achieve this goal, we will use a combination of cell and virus culture, molecular biology techniques, and Nano Flow Cytometry to study RTN3-mediated DENV exosome loading. Specifically, we will use RT-qPCR, western blotting, and flow cytometry to characterize exosomes secreted by infected cells. We will also assess the effects of RTN3 knockdown and overexpression on DENV exosome loading. This summer student project is particularly important since DENV is a re-emerging virus with pandemic potential and DENV exosomes can compromise vaccines and therapeutics. Understanding how RTN3 modulates DENV exosome loading will provide valuable information for developing effective DENV vaccines and therapeutics.